Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency

Emanuela Setola, Lucilla D. Monti, Roberto Lanzi, Pietro Lucotti, Marco Losa, Elisa Gatti, Elena Galluccio, Matteo Oldani, Isabella Fermo, Massimo Giovannelli, Emanuele Bosi, PierMarco Piatti

Research output: Contribution to journalArticle

16 Citations (Scopus)

Abstract

Patients with growth hormone deficiency (GHD) are known to have reduced life expectancy due to increased cardiovascular and cerebrovascular events. An increase in asymmetric dimethylarginine (ADMA) levels previously found in GHD patients could promote premature atherosclerosis. The aim of this study was to determine whether 6-month growth hormone (GH) replacement therapy was able to decrease ADMA levels and ameliorate endothelial dysfunction. Thirty-one GHD patients were studied before and after 6 months of GH (4 μg/[kg d], daily) replacement therapy. Reduced pretreatment levels of serum insulin-like growth factor (IGF) 1 were normalized during GH treatment (88.2 ± 62.5 to 191.7 ± 80.3 ng/mL, P <.0001). After 6 months of GH replacement, plasma cyclic guanosine monophosphate levels significantly increased (2.14 ± 0.52 to 3.54 ± 1.2 ng/mL, P <.0001), serum ADMA levels were significantly decreased (0.65 ± 0.1 vs 0.59 ± 0.11 μmol/L, P <.05), and arganine (Arg) to ADMA ratio was significantly higher (155 ± 53 vs 193 ± 61, P <.01). No changes were observed for plasma nitric oxide end products (nitrite and nitrate) levels after GH treatment (21.9 ± 14.9 vs 24.1 ± 19.0 μmol/L, not significant). Basal forearm blood flow remained unchanged, whereas reactive hyperemia increased from 7.30 ± 5.31 mL/100 mL forearm per minute before GH therapy to 13.18 ± 7.30 mL/100 mL forearm per minute after 6 months of therapy (P <.001). There was a positive correlation between IGF-1 and cyclic guanosine monophosphate (r = 0.73, P <.0001), IGF-1 and reactive hyperemia (r = 0.63, P <.0001), and IGF-1 and Arg/ADMA ratio (r = 0.44, P <.01). Conversely, a negative correlation was found between IGF-1 and ADMA levels (r = -0.41, P <.02). At the end of the study period, fat-free mass, plasma glucose, and hemoglobin A1c levels significantly increased, even if they were still in the reference range, suggesting moderate alteration of glucose metabolism. In conclusion, in GHD patients, GH replacement contributes to decreased, to some extent, cardiovascular risk, reducing ADMA levels and improving Arg/ADMA ratio and endothelial dysfunction.

Original languageEnglish
Pages (from-to)1685-1690
Number of pages6
JournalMetabolism
Volume57
Issue number12
DOIs
Publication statusPublished - Dec 2008

Fingerprint

Growth Hormone
Arginine
Somatomedins
Forearm
Therapeutics
Cyclic GMP
Hyperemia
N,N-dimethylarginine
Glucose
Hormone Replacement Therapy
Nitrites
Life Expectancy
Serum
Nitrates
Atherosclerosis
Nitric Oxide
Reference Values
Hemoglobins
Fats

ASJC Scopus subject areas

  • Endocrinology
  • Endocrinology, Diabetes and Metabolism

Cite this

Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency. / Setola, Emanuela; Monti, Lucilla D.; Lanzi, Roberto; Lucotti, Pietro; Losa, Marco; Gatti, Elisa; Galluccio, Elena; Oldani, Matteo; Fermo, Isabella; Giovannelli, Massimo; Bosi, Emanuele; Piatti, PierMarco.

In: Metabolism, Vol. 57, No. 12, 12.2008, p. 1685-1690.

Research output: Contribution to journalArticle

@article{1f5f208388524a10a002ae4edd77daab,
title = "Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency",
abstract = "Patients with growth hormone deficiency (GHD) are known to have reduced life expectancy due to increased cardiovascular and cerebrovascular events. An increase in asymmetric dimethylarginine (ADMA) levels previously found in GHD patients could promote premature atherosclerosis. The aim of this study was to determine whether 6-month growth hormone (GH) replacement therapy was able to decrease ADMA levels and ameliorate endothelial dysfunction. Thirty-one GHD patients were studied before and after 6 months of GH (4 μg/[kg d], daily) replacement therapy. Reduced pretreatment levels of serum insulin-like growth factor (IGF) 1 were normalized during GH treatment (88.2 ± 62.5 to 191.7 ± 80.3 ng/mL, P <.0001). After 6 months of GH replacement, plasma cyclic guanosine monophosphate levels significantly increased (2.14 ± 0.52 to 3.54 ± 1.2 ng/mL, P <.0001), serum ADMA levels were significantly decreased (0.65 ± 0.1 vs 0.59 ± 0.11 μmol/L, P <.05), and arganine (Arg) to ADMA ratio was significantly higher (155 ± 53 vs 193 ± 61, P <.01). No changes were observed for plasma nitric oxide end products (nitrite and nitrate) levels after GH treatment (21.9 ± 14.9 vs 24.1 ± 19.0 μmol/L, not significant). Basal forearm blood flow remained unchanged, whereas reactive hyperemia increased from 7.30 ± 5.31 mL/100 mL forearm per minute before GH therapy to 13.18 ± 7.30 mL/100 mL forearm per minute after 6 months of therapy (P <.001). There was a positive correlation between IGF-1 and cyclic guanosine monophosphate (r = 0.73, P <.0001), IGF-1 and reactive hyperemia (r = 0.63, P <.0001), and IGF-1 and Arg/ADMA ratio (r = 0.44, P <.01). Conversely, a negative correlation was found between IGF-1 and ADMA levels (r = -0.41, P <.02). At the end of the study period, fat-free mass, plasma glucose, and hemoglobin A1c levels significantly increased, even if they were still in the reference range, suggesting moderate alteration of glucose metabolism. In conclusion, in GHD patients, GH replacement contributes to decreased, to some extent, cardiovascular risk, reducing ADMA levels and improving Arg/ADMA ratio and endothelial dysfunction.",
author = "Emanuela Setola and Monti, {Lucilla D.} and Roberto Lanzi and Pietro Lucotti and Marco Losa and Elisa Gatti and Elena Galluccio and Matteo Oldani and Isabella Fermo and Massimo Giovannelli and Emanuele Bosi and PierMarco Piatti",
year = "2008",
month = "12",
doi = "10.1016/j.metabol.2008.07.024",
language = "English",
volume = "57",
pages = "1685--1690",
journal = "Metabolism: Clinical and Experimental",
issn = "0026-0495",
publisher = "W.B. Saunders Ltd",
number = "12",

}

TY - JOUR

T1 - Effects of growth hormone treatment on arginine to asymmetric dimethylarginine ratio and endothelial function in patients with growth hormone deficiency

AU - Setola, Emanuela

AU - Monti, Lucilla D.

AU - Lanzi, Roberto

AU - Lucotti, Pietro

AU - Losa, Marco

AU - Gatti, Elisa

AU - Galluccio, Elena

AU - Oldani, Matteo

AU - Fermo, Isabella

AU - Giovannelli, Massimo

AU - Bosi, Emanuele

AU - Piatti, PierMarco

PY - 2008/12

Y1 - 2008/12

N2 - Patients with growth hormone deficiency (GHD) are known to have reduced life expectancy due to increased cardiovascular and cerebrovascular events. An increase in asymmetric dimethylarginine (ADMA) levels previously found in GHD patients could promote premature atherosclerosis. The aim of this study was to determine whether 6-month growth hormone (GH) replacement therapy was able to decrease ADMA levels and ameliorate endothelial dysfunction. Thirty-one GHD patients were studied before and after 6 months of GH (4 μg/[kg d], daily) replacement therapy. Reduced pretreatment levels of serum insulin-like growth factor (IGF) 1 were normalized during GH treatment (88.2 ± 62.5 to 191.7 ± 80.3 ng/mL, P <.0001). After 6 months of GH replacement, plasma cyclic guanosine monophosphate levels significantly increased (2.14 ± 0.52 to 3.54 ± 1.2 ng/mL, P <.0001), serum ADMA levels were significantly decreased (0.65 ± 0.1 vs 0.59 ± 0.11 μmol/L, P <.05), and arganine (Arg) to ADMA ratio was significantly higher (155 ± 53 vs 193 ± 61, P <.01). No changes were observed for plasma nitric oxide end products (nitrite and nitrate) levels after GH treatment (21.9 ± 14.9 vs 24.1 ± 19.0 μmol/L, not significant). Basal forearm blood flow remained unchanged, whereas reactive hyperemia increased from 7.30 ± 5.31 mL/100 mL forearm per minute before GH therapy to 13.18 ± 7.30 mL/100 mL forearm per minute after 6 months of therapy (P <.001). There was a positive correlation between IGF-1 and cyclic guanosine monophosphate (r = 0.73, P <.0001), IGF-1 and reactive hyperemia (r = 0.63, P <.0001), and IGF-1 and Arg/ADMA ratio (r = 0.44, P <.01). Conversely, a negative correlation was found between IGF-1 and ADMA levels (r = -0.41, P <.02). At the end of the study period, fat-free mass, plasma glucose, and hemoglobin A1c levels significantly increased, even if they were still in the reference range, suggesting moderate alteration of glucose metabolism. In conclusion, in GHD patients, GH replacement contributes to decreased, to some extent, cardiovascular risk, reducing ADMA levels and improving Arg/ADMA ratio and endothelial dysfunction.

AB - Patients with growth hormone deficiency (GHD) are known to have reduced life expectancy due to increased cardiovascular and cerebrovascular events. An increase in asymmetric dimethylarginine (ADMA) levels previously found in GHD patients could promote premature atherosclerosis. The aim of this study was to determine whether 6-month growth hormone (GH) replacement therapy was able to decrease ADMA levels and ameliorate endothelial dysfunction. Thirty-one GHD patients were studied before and after 6 months of GH (4 μg/[kg d], daily) replacement therapy. Reduced pretreatment levels of serum insulin-like growth factor (IGF) 1 were normalized during GH treatment (88.2 ± 62.5 to 191.7 ± 80.3 ng/mL, P <.0001). After 6 months of GH replacement, plasma cyclic guanosine monophosphate levels significantly increased (2.14 ± 0.52 to 3.54 ± 1.2 ng/mL, P <.0001), serum ADMA levels were significantly decreased (0.65 ± 0.1 vs 0.59 ± 0.11 μmol/L, P <.05), and arganine (Arg) to ADMA ratio was significantly higher (155 ± 53 vs 193 ± 61, P <.01). No changes were observed for plasma nitric oxide end products (nitrite and nitrate) levels after GH treatment (21.9 ± 14.9 vs 24.1 ± 19.0 μmol/L, not significant). Basal forearm blood flow remained unchanged, whereas reactive hyperemia increased from 7.30 ± 5.31 mL/100 mL forearm per minute before GH therapy to 13.18 ± 7.30 mL/100 mL forearm per minute after 6 months of therapy (P <.001). There was a positive correlation between IGF-1 and cyclic guanosine monophosphate (r = 0.73, P <.0001), IGF-1 and reactive hyperemia (r = 0.63, P <.0001), and IGF-1 and Arg/ADMA ratio (r = 0.44, P <.01). Conversely, a negative correlation was found between IGF-1 and ADMA levels (r = -0.41, P <.02). At the end of the study period, fat-free mass, plasma glucose, and hemoglobin A1c levels significantly increased, even if they were still in the reference range, suggesting moderate alteration of glucose metabolism. In conclusion, in GHD patients, GH replacement contributes to decreased, to some extent, cardiovascular risk, reducing ADMA levels and improving Arg/ADMA ratio and endothelial dysfunction.

UR - http://www.scopus.com/inward/record.url?scp=55649091391&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=55649091391&partnerID=8YFLogxK

U2 - 10.1016/j.metabol.2008.07.024

DO - 10.1016/j.metabol.2008.07.024

M3 - Article

VL - 57

SP - 1685

EP - 1690

JO - Metabolism: Clinical and Experimental

JF - Metabolism: Clinical and Experimental

SN - 0026-0495

IS - 12

ER -